Abstract 1517
Background
Previous studies have demonstrated an association between type 2 diabetes mellitus (T2DM) and several types of cancers. However, the role of T2DM in pancreatic neuroendocrine tumors (pNETs) has not been systemically studied.
Methods
A retrospective, follow-up cohort analysis including 299 patients with pNETs was performed. The clinicopathologic characteristics between diabetics and nondiabetic were compared. The overall survival (OS) and progression-free survival (PFS) separated by diabetics and nondiabetic status were analyzed. The association between metformin use and survival was assessed to confirm whether metformin has an impact on prognosis of pNETs.
Results
The prevalence of T2DM was 20.7% (n = 62) in the cohort. For both OS and PFS, diabetic status was associated with a dismal outcome in univariate analyses, and the association was not exist when controlled by stage. The proportion of grade 3 tumor, distant metastasis and nerve invasion was higher in pNETs patients with T2DM than that of patients without T2DM. According to the result of logit regression, pNETs patients with T2DM were at high risk of tumor metastasis (OR = 2.81, P = 0.001), nerve invasion (OR = 2.43, P = 0.029) and grade 3 tumor (OR = 4.97, P = 0.010). Multivariate analysis demonstrated that T2DM was not an independent predictor of OS (P = 0.742) and PFS (P = 0.917). In subset analysis, no significant differences were observed for OS and PFS in subgroup according to their metformin usage.
Conclusions
T2DM is associated with pNETs growth and metastasis, and is not an independent risk factor of poor prognosis in patients with pNETs. No significant association is found between metformin use and survival in pNETs patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xianjun Yu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3780 - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
Presenter: Salah-Eddin Al-Batran
Session: Poster Display session 2
Resources:
Abstract
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract